{"success":true,"data":{"pressRelease":{"id":"154938","rtpr_id":"nPreLY01Ya-20260929","ticker":"NOVOB","exchange":"Nasdaq Copenhagen","all_tickers":["NOVOB"],"title":"Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD","author":"PR Newswire","published_at":"2026-09-29T10:00:04.986Z","article_body":"Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major\nadverse cardiovascular events (death, heart attack, and stroke) in adults with\ntype 2 diabetes compared to switching to Mounjaro® (tirzepatide), in\nreal-world analysis at EASD\nPR Newswire\n\nPLAINSBORO, N.J. and BAGSVÆRD, Denmark, Sept. 29, 2026\n* Adults with type 2 diabetes on semaglutide injection 1 mg, whose dose was\nincreased to 2 mg, were associated with a statistically significant 6% lower\nrisk of major adverse cardiovascular events (MACE), compared to switching to\ntirzepatide (up to 15 mg)(1)\n* Retrospective real-world analysis of claims data for 636,525 adults living\nwith type 2 diabetes compared outcomes for those escalated to semaglutide 2 mg\nversus switching to tirzepatide(1)\n* Results from the COMPETE SWITCH CV study provide insights into GLP-1 RA\ntreatment adjustment in adults with type 2 diabetes\nPLAINSBORO, N.J. and BAGSVÆRD, Denmark, Sept. 29, 2026 /PRNewswire/ -- Novo\nNordisk today announced new retrospective real-world evidence in adults with\ntype 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the\nanalysis, adults who escalated to semaglutide injection 2 mg were associated\nwith a statistically significant 6% lower risk of major adverse cardiovascular\nevents (MACE), including all-cause death, myocardial infarction (heart\nattack), and stroke, than those who switched to tirzepatide up to 15 mg\n(Adjusted HR 1.06; 95% CI 1.04-1.08; P=0.005).(1) These findings were\npresented at the European Association for the Study of Diabetes (EASD) Annual\nMeeting 2026 in Milan, Italy.\n\n\"For people with type 2 diabetes, switching therapies or adjusting dosages are\noften necessary to achieve glycemic control — still, cardiovascular risk\nshould also remain an important consideration,\" said Michael Radin, MD,\nexecutive medical director at Novo. \"These data may help inform healthcare\nprofessionals facing a critical challenge: whether to increase the dosage or\nswitch to another therapy for an adult with type 2 diabetes who is already\ntreated with semaglutide. These real-world findings can help provide insights\ninto how intensification strategies may affect cardiovascular outcomes as an\nimportant factor in patient care.\"\n\nIn this analysis of 636,525 adults with type 2 diabetes receiving semaglutide\n1 mg, 67.2% remained on semaglutide 1 mg, whereas 29.2% of patients had\nescalated their dose to semaglutide 2 mg, and 3.6% had switched to tirzepatide\nwithin 365 days after the index date (the date of the first prescription fill\nfor semaglutide 1 mg). At the 720-day follow up, fewer patients remained on\nsemaglutide 1 mg (57.4%), reflecting continued treatment intensification over\ntime, with 36.9% escalating to semaglutide 2 mg and 5.7% switching to\ntirzepatide.(1) After switching to an initial tirzepatide dose of either 2.5\nmg or 5 mg, clinicians had the flexibility to titrate across the tirzepatide\ndosing regimen, where approximately 31% of patients who switched to\ntirzepatide reached ≥10 mg dose during follow-up.(1) A subset of the study\ncohort evaluated patients with type 2 diabetes and more than one HbA1c and /or\nweight measurement at baseline and demonstrated consistent results (Adjusted\nHR, 1.07 [95% CI, 1.01-1.13], P<0.035).(1) Safety outcomes were not assessed\nin this analysis.\n\n\"Treatment intensification is a common challenge we face in clinical practice,\nparticularly for adults with type 2 diabetes who have not yet met their\ntreatment goals but are otherwise tolerating their current regimen well,\" said\nKathryn S. Tierney, MSN, APRN, FNP-BC, FAANP, Middlesex Health MultiSpecialty\nGroup in Middletown, CT. \"These real-world findings suggest that escalating to\nsemaglutide 2 mg may be a meaningful option for appropriate patients, as\nintensification of treatment was associated with a lower risk of major adverse\ncardiovascular events than those who switched therapies. The analysis\nreinforces the importance of considering cardiovascular outcomes, alongside\nglycemic management, when making treatment decisions.\"\n\nThese findings build upon an earlier analysis of these data, which examined\nHbA(1c) and weight loss.(2)\n\nReal-world study data can provide valuable insights into how treatments work\noutside of controlled clinical trial settings. Real-world data analyses also\nhave several limitations; results may reflect residual unmeasured confounding,\nwhile associations can be demonstrated, causal relationships cannot be\ndefinitively established. Additionally, use of retrospective claims data may\nexclude patients with intermittent coverage or underserved populations,\npotentially limiting generalizability.(3)\n\nIt is important to note that semaglutide injection contains a Boxed Warning\nfor possible thyroid tumors, including cancer, and should not be used in those\nwith a personal or family history of medullary thyroid carcinoma (MTC) or\nMultiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side\neffects include nausea, vomiting, diarrhea, stomach (abdominal) pain, and\nconstipation.\n\nAbout COMPETE SWITCH Cardiovascular (CV)\nCOMPETE SWITCH is a retrospective cohort study using Komodo Health's\nHealthcare Map with linked laboratory results, a large US healthcare claims\ndatabase (January 2018–September 2025). The study evaluated real-world\ntreatment patterns among adults with type 2 diabetes receiving semaglutide 1\nmg, specifically comparing outcomes after dose escalation to semaglutide 2 mg\nversus switching to tirzepatide.(2) The cardiovascular component of COMPETE\nSWITCH assessed MACE using an intention-to-treat approach and included 185,705\nadults who escalated to semaglutide 2 mg and 23,104 adults who switched to\ntirzepatide all of whom were followed from the point of either dose escalation\nor switching or end of study period.(1) Overall, the collective COMPETE\nSWITCH analyses offer real-world insight into cardiometabolic outcomes\nassociated with treatment strategies and decisions in adults with type 2\ndiabetes. Because treatment effects may vary across individuals (low or high\nresponders), heterogeneity may have significant impact on studies of dose\ntitration and multiple sequential dosing.\n\nNovo is the global healthcare company that believes lasting health starts now.\nFor over a century, we've combined leading scientific expertise with a deep\nunderstanding of people's lives. We develop treatments and support that help\nmillions of people make progress they can see, feel and sustain now and in the\nfuture. Every day, over 67,000 employees around the world advance our purpose\nto drive change for lasting health. Through our partnerships, programs and\ninvestments, we're working to prevent disease, expand access to treatments and\nreduce our environmental impact to help even more people live healthier lives.\nIn the United States, Novo has a 40-year presence, is headquartered in New\nJersey and employs approximately 10,000 people. For more information, visit\nnovonordisk.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=13739112&u=https%3A%2F%2Fwww.novonordisk.com%2F&a=novonordisk.com)\nand novonordisk-us.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=4104025893&u=https%3A%2F%2Fwww.novonordisk-us.com%2F&a=novonordisk-us.com)\nand follow us on Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=3131060346&u=https%3A%2F%2Fwww.instagram.com%2Fnovonordiskus%2F&a=Instagram),\nLinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=1869266986&u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnovo-nordisk&a=LinkedIn),\nTikTok\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=1484454395&u=https%3A%2F%2Fwww.tiktok.com%2F%40novonordiskus&a=TikTok),\nFacebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=3558208282&u=https%3A%2F%2Fwww.facebook.com%2FNovoNordiskUS%2F&a=Facebook),\nX\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=1985287470&u=https%3A%2F%2Fx.com%2Fnovonordiskus&a=X)\nand YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=348191959&u=http%3A%2F%2Fwww.youtube.com%2Fnovonordisk&a=YouTube).\n\n Contacts for further information \n \n Novo Media: \n Ambre James-Brown +45 3079 9289 Liz Skrbkova (US) \n globalmedia@novonordisk.com +1 609 917 0632 \n USMediaRelations@novonordisk.com \n \n Novo Investors: \n Michael Novod +45 3075 6050 Sina Meyer +45 3079 6656 \n nvno@novonordisk.com azey@novonordisk.com \n \n Christoffer Togo Solgaard-Tullin +45 3079 1471 \n cftu@novonordisk.com \n \n Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com Mads Berner Bruun +45 3075 2936 \n mbbz@novonordisk.com \n \n Frederik Taylor Pitter (US) +1 609 613 0568 Alex Bruce (US) +1 640 230 0276 \n fptr@novonordisk.com axeu@novonordisk.com \n\nOZEMPIC, NOVO NORDISK, NOVO, and the Apis Bull Logo are trademarks owned by\nNovo Nordisk A/S.\nAll other trademarks, registered or unregistered, are the property of their\nrespective owners.\n© 2026 Novo Nordisk All rights reserved. US26OZM00636 September 2026\n\nReferences\n1. COMPETE SWITCH CV. Novo Nordisk Data on file.\n2. Fang G, Muhammad C, Swift C, et al. Cardiometabolic outcomes in adults with\nT2D treated with 1 mg semaglutide who titrate to 2 mg semaglutide vs switch to\ntirzepatide. Poster presentation at the American Diabetes Association\nScientific Sessions; 5-8 June 2026, New Orleans, LA.\n3. Dang A. Real-world evidence: a primer. Pharm Med 37, 25–36 (2023).\nhttps://doi.org/10.1007/s40290-022-00456-6\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/novos-ozempic-semaglutide-2-mg-associated-with-lower-risk-of-major-adverse-cardiovascular-events-death-heart-attack-and-stroke-in-adults-with-type-2-diabetes-compared-to-switching-to-mounjaro-tirzepatide-in-real-world--302892062.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1989915/Novo-Logo.jpg?id=OA2975372\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPreLY01Ya-20260929","title":"Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD","author":"PR Newswire","ticker":"NOVOB","created":"2026-09-29T10:00:04.986Z","tickers":["NOVOB"],"exchange":"Nasdaq Copenhagen","article_body":"Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major\nadverse cardiovascular events (death, heart attack, and stroke) in adults with\ntype 2 diabetes compared to switching to Mounjaro® (tirzepatide), in\nreal-world analysis at EASD\nPR Newswire\n\nPLAINSBORO, N.J. and BAGSVÆRD, Denmark, Sept. 29, 2026\n* Adults with type 2 diabetes on semaglutide injection 1 mg, whose dose was\nincreased to 2 mg, were associated with a statistically significant 6% lower\nrisk of major adverse cardiovascular events (MACE), compared to switching to\ntirzepatide (up to 15 mg)(1)\n* Retrospective real-world analysis of claims data for 636,525 adults living\nwith type 2 diabetes compared outcomes for those escalated to semaglutide 2 mg\nversus switching to tirzepatide(1)\n* Results from the COMPETE SWITCH CV study provide insights into GLP-1 RA\ntreatment adjustment in adults with type 2 diabetes\nPLAINSBORO, N.J. and BAGSVÆRD, Denmark, Sept. 29, 2026 /PRNewswire/ -- Novo\nNordisk today announced new retrospective real-world evidence in adults with\ntype 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the\nanalysis, adults who escalated to semaglutide injection 2 mg were associated\nwith a statistically significant 6% lower risk of major adverse cardiovascular\nevents (MACE), including all-cause death, myocardial infarction (heart\nattack), and stroke, than those who switched to tirzepatide up to 15 mg\n(Adjusted HR 1.06; 95% CI 1.04-1.08; P=0.005).(1) These findings were\npresented at the European Association for the Study of Diabetes (EASD) Annual\nMeeting 2026 in Milan, Italy.\n\n\"For people with type 2 diabetes, switching therapies or adjusting dosages are\noften necessary to achieve glycemic control — still, cardiovascular risk\nshould also remain an important consideration,\" said Michael Radin, MD,\nexecutive medical director at Novo. \"These data may help inform healthcare\nprofessionals facing a critical challenge: whether to increase the dosage or\nswitch to another therapy for an adult with type 2 diabetes who is already\ntreated with semaglutide. These real-world findings can help provide insights\ninto how intensification strategies may affect cardiovascular outcomes as an\nimportant factor in patient care.\"\n\nIn this analysis of 636,525 adults with type 2 diabetes receiving semaglutide\n1 mg, 67.2% remained on semaglutide 1 mg, whereas 29.2% of patients had\nescalated their dose to semaglutide 2 mg, and 3.6% had switched to tirzepatide\nwithin 365 days after the index date (the date of the first prescription fill\nfor semaglutide 1 mg). At the 720-day follow up, fewer patients remained on\nsemaglutide 1 mg (57.4%), reflecting continued treatment intensification over\ntime, with 36.9% escalating to semaglutide 2 mg and 5.7% switching to\ntirzepatide.(1) After switching to an initial tirzepatide dose of either 2.5\nmg or 5 mg, clinicians had the flexibility to titrate across the tirzepatide\ndosing regimen, where approximately 31% of patients who switched to\ntirzepatide reached ≥10 mg dose during follow-up.(1) A subset of the study\ncohort evaluated patients with type 2 diabetes and more than one HbA1c and /or\nweight measurement at baseline and demonstrated consistent results (Adjusted\nHR, 1.07 [95% CI, 1.01-1.13], P<0.035).(1) Safety outcomes were not assessed\nin this analysis.\n\n\"Treatment intensification is a common challenge we face in clinical practice,\nparticularly for adults with type 2 diabetes who have not yet met their\ntreatment goals but are otherwise tolerating their current regimen well,\" said\nKathryn S. Tierney, MSN, APRN, FNP-BC, FAANP, Middlesex Health MultiSpecialty\nGroup in Middletown, CT. \"These real-world findings suggest that escalating to\nsemaglutide 2 mg may be a meaningful option for appropriate patients, as\nintensification of treatment was associated with a lower risk of major adverse\ncardiovascular events than those who switched therapies. The analysis\nreinforces the importance of considering cardiovascular outcomes, alongside\nglycemic management, when making treatment decisions.\"\n\nThese findings build upon an earlier analysis of these data, which examined\nHbA(1c) and weight loss.(2)\n\nReal-world study data can provide valuable insights into how treatments work\noutside of controlled clinical trial settings. Real-world data analyses also\nhave several limitations; results may reflect residual unmeasured confounding,\nwhile associations can be demonstrated, causal relationships cannot be\ndefinitively established. Additionally, use of retrospective claims data may\nexclude patients with intermittent coverage or underserved populations,\npotentially limiting generalizability.(3)\n\nIt is important to note that semaglutide injection contains a Boxed Warning\nfor possible thyroid tumors, including cancer, and should not be used in those\nwith a personal or family history of medullary thyroid carcinoma (MTC) or\nMultiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side\neffects include nausea, vomiting, diarrhea, stomach (abdominal) pain, and\nconstipation.\n\nAbout COMPETE SWITCH Cardiovascular (CV)\nCOMPETE SWITCH is a retrospective cohort study using Komodo Health's\nHealthcare Map with linked laboratory results, a large US healthcare claims\ndatabase (January 2018–September 2025). The study evaluated real-world\ntreatment patterns among adults with type 2 diabetes receiving semaglutide 1\nmg, specifically comparing outcomes after dose escalation to semaglutide 2 mg\nversus switching to tirzepatide.(2) The cardiovascular component of COMPETE\nSWITCH assessed MACE using an intention-to-treat approach and included 185,705\nadults who escalated to semaglutide 2 mg and 23,104 adults who switched to\ntirzepatide all of whom were followed from the point of either dose escalation\nor switching or end of study period.(1) Overall, the collective COMPETE\nSWITCH analyses offer real-world insight into cardiometabolic outcomes\nassociated with treatment strategies and decisions in adults with type 2\ndiabetes. Because treatment effects may vary across individuals (low or high\nresponders), heterogeneity may have significant impact on studies of dose\ntitration and multiple sequential dosing.\n\nNovo is the global healthcare company that believes lasting health starts now.\nFor over a century, we've combined leading scientific expertise with a deep\nunderstanding of people's lives. We develop treatments and support that help\nmillions of people make progress they can see, feel and sustain now and in the\nfuture. Every day, over 67,000 employees around the world advance our purpose\nto drive change for lasting health. Through our partnerships, programs and\ninvestments, we're working to prevent disease, expand access to treatments and\nreduce our environmental impact to help even more people live healthier lives.\nIn the United States, Novo has a 40-year presence, is headquartered in New\nJersey and employs approximately 10,000 people. For more information, visit\nnovonordisk.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=13739112&u=https%3A%2F%2Fwww.novonordisk.com%2F&a=novonordisk.com)\nand novonordisk-us.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=4104025893&u=https%3A%2F%2Fwww.novonordisk-us.com%2F&a=novonordisk-us.com)\nand follow us on Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=3131060346&u=https%3A%2F%2Fwww.instagram.com%2Fnovonordiskus%2F&a=Instagram),\nLinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=1869266986&u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnovo-nordisk&a=LinkedIn),\nTikTok\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=1484454395&u=https%3A%2F%2Fwww.tiktok.com%2F%40novonordiskus&a=TikTok),\nFacebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=3558208282&u=https%3A%2F%2Fwww.facebook.com%2FNovoNordiskUS%2F&a=Facebook),\nX\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=1985287470&u=https%3A%2F%2Fx.com%2Fnovonordiskus&a=X)\nand YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784621-1&h=348191959&u=http%3A%2F%2Fwww.youtube.com%2Fnovonordisk&a=YouTube).\n\n Contacts for further information \n \n Novo Media: \n Ambre James-Brown +45 3079 9289 Liz Skrbkova (US) \n globalmedia@novonordisk.com +1 609 917 0632 \n USMediaRelations@novonordisk.com \n \n Novo Investors: \n Michael Novod +45 3075 6050 Sina Meyer +45 3079 6656 \n nvno@novonordisk.com azey@novonordisk.com \n \n Christoffer Togo Solgaard-Tullin +45 3079 1471 \n cftu@novonordisk.com \n \n Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com Mads Berner Bruun +45 3075 2936 \n mbbz@novonordisk.com \n \n Frederik Taylor Pitter (US) +1 609 613 0568 Alex Bruce (US) +1 640 230 0276 \n fptr@novonordisk.com axeu@novonordisk.com \n\nOZEMPIC, NOVO NORDISK, NOVO, and the Apis Bull Logo are trademarks owned by\nNovo Nordisk A/S.\nAll other trademarks, registered or unregistered, are the property of their\nrespective owners.\n© 2026 Novo Nordisk All rights reserved. US26OZM00636 September 2026\n\nReferences\n1. COMPETE SWITCH CV. Novo Nordisk Data on file.\n2. Fang G, Muhammad C, Swift C, et al. Cardiometabolic outcomes in adults with\nT2D treated with 1 mg semaglutide who titrate to 2 mg semaglutide vs switch to\ntirzepatide. Poster presentation at the American Diabetes Association\nScientific Sessions; 5-8 June 2026, New Orleans, LA.\n3. Dang A. Real-world evidence: a primer. Pharm Med 37, 25–36 (2023).\nhttps://doi.org/10.1007/s40290-022-00456-6\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/novos-ozempic-semaglutide-2-mg-associated-with-lower-risk-of-major-adverse-cardiovascular-events-death-heart-attack-and-stroke-in-adults-with-type-2-diabetes-compared-to-switching-to-mounjaro-tirzepatide-in-real-world--302892062.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1989915/Novo-Logo.jpg?id=OA2975372\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-29T10:00:05.06764059Z","server_sent_at_ms":1790676005067},"received_at":"2026-09-29T10:00:05.120Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}